These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 27472649

  • 21. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.
    Votanopoulos KI, Sugarbaker P, Deraco M, Morris D, Glehen O, Elias D, De Simone M, Robella M, Heyd B, Kusamura S, Baratti D, Chouliaras K, Russell G, Shen P, Levine EA, RENAPE Working Group.
    Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418
    [Abstract] [Full Text] [Related]

  • 22. Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia.
    Galan A, Rousset P, Mercier F, Képénékian V, Valette PJ, Glehen O, Passot G.
    Eur J Surg Oncol; 2018 Nov; 44(11):1818-1823. PubMed ID: 30143249
    [Abstract] [Full Text] [Related]

  • 23. Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China.
    Su YD, Yang ZR, Li XB, Yu Y, Du XM, Li Y.
    Int J Hyperthermia; 2022 Nov; 39(1):706-712. PubMed ID: 35485308
    [Abstract] [Full Text] [Related]

  • 24. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    van Eden WJ, Elekonawo FMK, Starremans BJ, Kok NFM, Bremers AJA, de Wilt JHW, Aalbers AGJ.
    Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
    [Abstract] [Full Text] [Related]

  • 25. Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival.
    Gilani SNS, Mehta A, Garcia-Fadrique A, Rowaiye B, Jenei V, Dayal S, Chandrakumaran K, Carr N, Mohamed F, Cecil T, Moran B.
    Int J Hyperthermia; 2018 Aug; 34(5):578-584. PubMed ID: 29431036
    [Abstract] [Full Text] [Related]

  • 26. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures.
    Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard AC, Bakrin N, Cotte E, Gilly FN, Glehen O.
    J Surg Oncol; 2016 Jun; 113(7):796-803. PubMed ID: 27110915
    [Abstract] [Full Text] [Related]

  • 27. Peritoneal mesothelioma in Sweden: A population-based study.
    Cashin PH, Jansson Palmer G, Asplund D, Graf W, Syk I.
    Cancer Med; 2019 Oct; 8(14):6468-6475. PubMed ID: 31483564
    [Abstract] [Full Text] [Related]

  • 28. Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases.
    Kyang LS, Alzahrani NA, Valle SJ, Rahman MK, Arrowaili A, Liauw W, Morris DL.
    J Surg Oncol; 2019 Sep; 120(4):794-802. PubMed ID: 31309588
    [Abstract] [Full Text] [Related]

  • 29. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study.
    Baratti D, Kusamura S, Cabras AD, Deraco M.
    Ann Surg Oncol; 2012 May; 19(5):1416-24. PubMed ID: 22302266
    [Abstract] [Full Text] [Related]

  • 30. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: morbidity and postoperative outcomes.
    Robella M, Vaira M, Cinquegrana A, De Simone M.
    Minerva Chir; 2019 Jun; 74(3):195-202. PubMed ID: 29589675
    [Abstract] [Full Text] [Related]

  • 31. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma.
    Klos D, Hanuliak J, Lemstrova R, Mohelnikova-Duchonova B, Zapletalova J, Melichar B, Risko J.
    Bratisl Lek Listy; 2023 Jun; 124(5):345-350. PubMed ID: 36876363
    [Abstract] [Full Text] [Related]

  • 32. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
    Li YC, Khashab T, Terhune J, Eckert RL, Hanna N, Burke A, Richard Alexander H.
    Ann Surg Oncol; 2017 Aug; 24(8):2259-2265. PubMed ID: 28324285
    [Abstract] [Full Text] [Related]

  • 33. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes.
    Deban M, Taqi K, Knapp GC, Soucisse M, Curry M, Sidéris L, Dubé P, Khaldi MA, Jedrzejko N, Porter G, Giacomantonio C, Hamilton T, MacNeill A, Mack L, Bouchard-Fortier A.
    J Surg Oncol; 2023 Sep; 128(4):595-603. PubMed ID: 37249154
    [Abstract] [Full Text] [Related]

  • 34. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
    Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH.
    J Clin Oncol; 2009 Dec 20; 27(36):6237-42. PubMed ID: 19917862
    [Abstract] [Full Text] [Related]

  • 35. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K, Sardi A, Munoz-Zuluaga C, Studeman K, Nieroda C, Sittig M, King MC, Sipok A, Gushchin V.
    Ann Surg Oncol; 2020 Jan 20; 27(1):179-187. PubMed ID: 31646450
    [Abstract] [Full Text] [Related]

  • 36. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.
    Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA.
    Ann Surg Oncol; 2014 Apr 20; 21(4):1159-65. PubMed ID: 24322529
    [Abstract] [Full Text] [Related]

  • 37. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
    Teo MC, Tan GH, Tham CK, Lim C, Soo KC.
    Ann Surg Oncol; 2013 Sep 20; 20(9):2968-74. PubMed ID: 23504144
    [Abstract] [Full Text] [Related]

  • 38. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X, Li Z, Li Z, Jia Y, Shan F, Ji X, Bu Z, Zhang L, Wu A, Ji J.
    J Surg Oncol; 2015 Jun 20; 111(7):840-7. PubMed ID: 25864884
    [Abstract] [Full Text] [Related]

  • 39. Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights From a Multi-Center Study.
    Yaşar S, Yılmaz F, Utkan G, Algın E, Bayram D, Tamam S, Öksüzoğlu ÖBÇ, İlhan A, Erdat EC, Ünal AE, Yalçın Ş.
    Ann Surg Oncol; 2024 Sep 20; 31(9):6228-6236. PubMed ID: 38806763
    [Abstract] [Full Text] [Related]

  • 40. A comprehensive review of childbearing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Papageorgiou D, Manatakis DK, Papakonstantinou K, Kyriazanos ID.
    Arch Gynecol Obstet; 2020 Oct 20; 302(4):793-799. PubMed ID: 32653946
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.